{"indexed":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T05:10:33Z","timestamp":1574485833386},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"URL":"http:\/\/www.springer.com\/tdm","start":{"date-parts":[[2013,2,11]],"date-time":"2013-02-11T00:00:00Z","timestamp":1360540800000},"delay-in-days":0,"content-version":"tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s12020-013-9895-0","type":"article-journal","created":{"date-parts":[[2013,2,10]],"date-time":"2013-02-10T09:54:56Z","timestamp":1360490096000},"page":"448-453","source":"Crossref","is-referenced-by-count":28,"title":"Predictors of long-term remission in patients with Graves\u2019 disease: a single center experience","prefix":"10.1007","volume":"44","author":[{"given":"Panagiotis","family":"Anagnostis","sequence":"first","affiliation":[]},{"given":"Fotini","family":"Adamidou","sequence":"additional","affiliation":[]},{"given":"Stergios A.","family":"Polyzos","sequence":"additional","affiliation":[]},{"given":"Simoni","family":"Katergari","sequence":"additional","affiliation":[]},{"given":"Eleni","family":"Karathanasi","sequence":"additional","affiliation":[]},{"given":"Chrisanthi","family":"Zouli","sequence":"additional","affiliation":[]},{"given":"Athanasios","family":"Panagiotou","sequence":"additional","affiliation":[]},{"given":"Marina","family":"Kita","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2013,2,11]]},"reference":[{"key":"9895_CR1","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1056\/NEJMcp0801880","volume":"358","author":"GA Brent","year":"2008","unstructured":"G.A. Brent, Graves\u2019 disease. N. Engl. J. Med. 358, 2594\u20132605 (2008)","journal-title":"N. Engl. J. Med."},{"key":"9895_CR2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.tem.2005.05.009","volume":"16","author":"M Schott","year":"2005","unstructured":"M. Schott, W.A. Scherbaum, N.G. Morgenthaler, Thyrotropin receptor autoantibodies in Graves\u2019 disease. Trends Endocrinol. Metab. 16, 243\u2013248 (2005)","journal-title":"Trends Endocrinol. Metab."},{"key":"9895_CR3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2265.1989.tb01244.x","volume":"31","author":"AJ Hedley","year":"1989","unstructured":"A.J. Hedley, R.E. Young, S.J. Jones, W.D. Alexander, P.D. Bewsher, Antithyroid drugs in the treatment of hyperthyroidism of Graves\u2019 disease: long-term follow-up of 434 patients. Scottish Automated Follow-Up Register Group. Clin. Endocrinol. (Oxf) 31, 209\u2013218 (1989)","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"9895_CR4","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra042972","volume":"352","author":"D Cooper","year":"2005","unstructured":"D. Cooper, Antithyroid drugs. N. Engl. J. Med. 352, 905\u2013917 (2005)","journal-title":"N. Engl. J. Med."},{"key":"9895_CR5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1530\/eje.1.01993","volume":"153","author":"P Abraham","year":"2005","unstructured":"P. Abraham, A. Avenell, C.M. Park, W.A. Watson, J.S. Bevan, A systematic review of drug therapy for Graves\u2019 hyperthyroidism. Eur. J. Endocrinol. 153, 489\u2013498 (2005)","journal-title":"Eur. J. Endocrinol."},{"key":"9895_CR6","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4158\/EP.17.3.456","volume":"17","author":"RS Bahn","year":"2011","unstructured":"R.S. Bahn, H.B. Burch, D.S. Cooper, J.R. Garber, M.C. Greenlee, I. Klein, P. Laurberg, I.R. McDougall, V.M. Montori, S.A. Rivkees, D.S. Ross, J.A. Sosa, M.N. Stan, American Thyroid Association, American Association of Clinical Endocrinologists, Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr. Pract. 17, 456\u2013520 (2011)","journal-title":"Endocr. Pract."},{"key":"9895_CR7","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1542\/peds.2007-1535","volume":"121","author":"NS Glaser","year":"2008","unstructured":"N.S. Glaser, D.M. Styne, Predicting the likelihood of remission in children with Graves\u2019 disease: a prospective, multicenter study. Pediatrics 121, e481\u2013e488 (2008)","journal-title":"Pediatrics"},{"key":"9895_CR8","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1210\/jc.2008-0842","volume":"93","author":"F Kaguelidou","year":"2008","unstructured":"F. Kaguelidou, C. Alberti, M. Castanet, M.A. Guitteny, P. Czernichow, J. L\u00e9ger, French Childhood Graves\u2019 Disease Study Group, Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J. Clin. Endocrinol. Metab. 93, 3817\u20133826 (2008)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"9895_CR9","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1210\/jc.85.3.1038","volume":"85","author":"A Allahabadia","year":"2000","unstructured":"A. Allahabadia, J. Daykin, R.L. Holder, M.C. Sheppard, S.C. Gough, J.A. Franklyn, Age and gender predict the outcome of treatment for Graves\u2019 hyperthyroidism. J. Clin. Endocrinol. Metab. 85, 1038\u20131042 (2000)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"9895_CR10","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1530\/acta.0.1200689","volume":"120","author":"H Schleusener","year":"1989","unstructured":"H. Schleusener, J. Schwander, C. Fischer, R. Holle, G. Holl, K. Badenhoop, J. Hensen, R. Finke, U. Bogner, W.R. Mayr et al., Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves\u2019 disease. Acta Endocrinol. (Copenh) 120, 689\u2013701 (1989)","journal-title":"Acta Endocrinol. (Copenh)"},{"key":"9895_CR11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1507\/endocrj.K06-069","volume":"54","author":"C Cappelli","year":"2007","unstructured":"C. Cappelli, E. Gandossi, M. Castellano, C. Pizzocaro, B. Agosti, A. Delbarba, I. Pirola, E. De Martino, E.A. Rosei, Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves\u2019 disease: a 120\u00a0months prospective study. Endocr. J. 54, 713\u2013720 (2007)","journal-title":"Endocr. J."},{"key":"9895_CR12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/thy.2006.16.295","volume":"16","author":"C Carella","year":"2006","unstructured":"C. Carella, G. Mazziotti, F. Sorvillo, M. Piscopo, M. Cioffi, P. Pilla, R. Nersita, S. Iorio, G. Amato, L.E. Braverman, E. Roti, Serum thyrotropin receptor antibodies concentrations in patients with Graves\u2019 disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and\/or thyroid response modify during the observation period. Thyroid 16, 295\u2013302 (2006)","journal-title":"Thyroid"},{"issue":"1","key":"9895_CR13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s12020-012-9789-6","volume":"43","author":"T Yasuda","year":"2012","unstructured":"T. Yasuda, Y. Okamoto, N. Hamada, K. Miyashita, M. Takahara, F. Sakamoto, T. Miyatsuka, T. Kitamura, N. Katakami, D. Kawamori, M. Otsuki, T.A. Matsuoka, H. Kaneto, I. Shimomura, Serum vitamin D levels are decreased in patients without remission of Graves\u2019 disease. Endocrine 43(1), 230\u2013232 (2012)","journal-title":"Endocrine"},{"key":"9895_CR14","unstructured":"M. Feng, H. Li, S.F. Chen, W.F. Li, F.B. Zhang, Polymorphisms in the vitamin D receptor gene and risk of autoimmune thyroid diseases: a meta-analysis. Endocrine, (2012). doi: 10.1007\/s12020-012-9812-y","DOI":"10.1007\/s12020-012-9812-y","doi-asserted-by":"crossref"},{"key":"9895_CR15","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1210\/jcem-70-3-675","volume":"70","author":"H Allannic","year":"1990","unstructured":"H. Allannic, R. Fauchet, J. Orgiazzi, A.M. Madec, B. Genetet, Y. Lorcy, A.M. Le Guerrier, C. Delambre, V. Derennes, Antithyroid drugs and Graves\u2019 disease: a prospective randomized evaluation of the efficacy of treatment duration. J. Clin. Endocrinol. Metab. 70, 675\u2013679 (1990)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"9895_CR16","first-page":"337","volume":"87","author":"AP Weetman","year":"1994","unstructured":"A.P. Weetman, A.P. Pickerill, P. Watson, V.K. Chatterjee, O.M. Edwards, Treatment of Graves\u2019 disease with the block-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse. QJM 87, 337\u2013341 (1994)","journal-title":"QJM"},{"key":"9895_CR17","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/BF03348811","volume":"15","author":"RVPC Garcia-Mayor","year":"1992","unstructured":"R.V.P.C. Garcia-Mayor, R. Luna-Cano, L.F. Perez-Mendez, J.C. Galofre, A. Andrade, Antithyroid drug and Graves\u2019 hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission. J. Endocrinol. Invest. 15, 815\u2013820 (1992)","journal-title":"J. Endocrinol. Invest."},{"key":"9895_CR18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2265.1999.00629.x","volume":"50","author":"D Maugendre","year":"1999","unstructured":"D. Maugendre, A. Gatel, L. Campion, C. Massart, I. Guilhem, Y. Lorcy, J. Lescouarch, J.Y. Herry, H. Allannic, Antithyroid drugs and Graves\u2019 disease\u2013prospective randomized assessment of long-term treatment. Clin. Endocrinol. (Oxf) 50, 127\u2013132 (1999)","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"9895_CR19","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1024\/0369-8394.95.29.1121","volume":"95","author":"T Wille","year":"2006","unstructured":"T. Wille, B. M\u00fcller, D. Noth, U. B\u00fcrgi, P. Diem, Long-term follow up after antithyroid drug treatment in Graves\u2019 disease. Praxis (Bern 1994) 95, 1121\u20131127 (2006)","journal-title":"Praxis (Bern 1994)"},{"key":"9895_CR20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1507\/endocrj.K10E-262","volume":"58","author":"T Konishi","year":"2011","unstructured":"T. Konishi, Y. Okamoto, M. Ueda, Y. Fukuda, I. Harusato, Y. Tsukamoto, N. Hamada, Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves\u2019 disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission. Endocr. J. 58, 95\u2013100 (2011)","journal-title":"Endocr. J."},{"key":"9895_CR21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1046\/j.1365-2265.1996.00800.x","volume":"45","author":"SR Page","year":"1996","unstructured":"S.R. Page, C.E. Sheard, M. Herbert, M. Hopton, W.J. Jeffcoate, A comparison of 20 or 40\u00a0mg per day of carbimazole in the initial treatment of hyperthyroidism. Clin. Endocrinol. (Oxf) 45, 511\u2013516 (1996)","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"9895_CR22","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1089\/thy.2009.0126","volume":"20","author":"YK Choo","year":"2010","unstructured":"Y.K. Choo, W.S. Yoo, D.W. Kim, H.K. Chung, Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves\u2019 disease. Thyroid 20, 949\u2013954 (2010)","journal-title":"Thyroid"},{"key":"9895_CR23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1530\/eje.0.1440475","volume":"144","author":"D Glinoer","year":"2001","unstructured":"D. Glinoer, P. de Nayer, M. Bex, Belgian Collaborative Study Group on Graves\u2019 Disease, Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves\u2019 hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur. J. Endocrinol. 144, 475\u2013483 (2001)","journal-title":"Eur. J. Endocrinol."},{"key":"9895_CR24","first-page":"307","volume":"54","author":"F Bola\u00f1os","year":"2002","unstructured":"F. Bola\u00f1os, M. Gonz\u00e1lez-Ortiz, H. Dur\u00f3n, C. S\u00e1nchez, Remission of Graves\u2019 hyperthyroidism treated with methimazole. Rev. Invest. Clin. 54, 307\u2013310 (2002)","journal-title":"Rev. Invest. Clin."},{"key":"9895_CR25","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199104043241403","volume":"324","author":"K Hashizume","year":"1991","unstructured":"K. Hashizume, K. Ichikawa, A. Sakurai, S. Suzuki, T. Takeda, M. Kobayashi, T. Miyamoto, M. Arai, T. Nagasawa, Administration of thyroxine in treated Graves\u2019 disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N. Engl. J. Med. 324, 947\u2013953 (1991)","journal-title":"N. Engl. J. Med."},{"key":"9895_CR26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1046\/j.1365-2265.1998.00446.x","volume":"48","author":"SK Grebe","year":"1998","unstructured":"S.K. Grebe, C.M. Feek, H.C. Ford, J.N. Fagerstr\u00f6m, D.P. Cordwell, J.W. Delahunt, R.J. Toomath, A randomized trial of short-term treatment of Graves\u2019 disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole. Clin. Endocrinol. (Oxf) 48, 585\u2013592 (1998)","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"9895_CR27","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1365-2265.1998.00554.x","volume":"49","author":"G Benker","year":"1998","unstructured":"G. Benker, D. Reinwein, G. Kahaly, L. Tegler, W.D. Alexander, J. Fassbinder, H. Hirche, Is there a methimazole dose effect on remission rate in Graves\u2019 disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs. Clin. Endocrinol. (Oxf) 49, 451\u2013457 (1998)","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"9895_CR28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1515\/jpem.2011.194","volume":"24","author":"H Sato","year":"2011","unstructured":"H. Sato, M. Minagawa, N. Sasaki, S. Sugihara, I. Kazukawa, K. Minamitani, K. Wataki, S. Konda, H. Inomata, K. Sanayama, Y. Kohno, Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves\u2019 disease: efficacy and adverse reactions during initial treatment and long-term outcome. J. Pediatr. Endocrinol. Metab. 24, 257\u2013263 (2011)","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"9895_CR29","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1532-5415.1994.tb04973.x","volume":"42","author":"T Yamada","year":"1994","unstructured":"T. Yamada, T. Aizawa, Y. Koizumi, I. Komiya, K. Ichikawa, K. Hashizume, Age-related therapeutic response to antithyroid drug in patients with hyperthyroid Graves\u2019 disease. J. Am. Geriatr. Soc. 42, 513\u2013516 (1994)","journal-title":"J. Am. Geriatr. Soc."},{"key":"9895_CR30","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/thy.1997.7.369","volume":"7","author":"P Vitti","year":"1997","unstructured":"P. Vitti, T. Rago, L. Chiovato, S. Pallini, F. Santini, E. Fiore, R. Rocchi, E. Martino, A. Pinchera, Clinical features of patients with Graves\u2019 disease undergoing remission after antithyroid drug treatment. Thyroid 7, 369\u2013375 (1997)","journal-title":"Thyroid"},{"key":"9895_CR31","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.25011\/cim.v32i3.6108","volume":"32","author":"H Cinemre","year":"2009","unstructured":"H. Cinemre, C. Bilir, F. Gokosmanoglu, N. Akdemir, B. Erdogmus, R. Buyukkaya, Predictors of time to remission and treatment failure in patients with Graves\u2019 disease treated with propylthiouracil. Clin. Invest. Med. 32, E199\u2013E205 (2009)","journal-title":"Clin. Invest. Med."},{"key":"9895_CR32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/BF01731833","volume":"23","author":"\u03a1 Prakash","year":"1996","unstructured":"\u03a1. Prakash, Prediction of remission in Graves\u2019 disease treated with long-term carbimazole therapy: evaluation of technetium-99\u00a0m thyroid uptake and TSH concentrations as prognostic indicators. Eur. J. Nucl. Med. 23, 118\u2013122 (1996)","journal-title":"Eur. J. Nucl. Med."},{"key":"9895_CR33","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1089\/thy.2005.15.1047","volume":"15","author":"B Quadbeck","year":"2005","unstructured":"B. Quadbeck, R. Hoermann, U. Roggenbuck, S. Hahn, K. Mann, O.E. Janssen, Basedow Study Group, Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves\u2019 disease. Thyroid 15, 1047\u20131054 (2005)","journal-title":"Thyroid"},{"key":"9895_CR34","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/pgmj.71.834.222","volume":"71","author":"WE Wood","year":"1995","unstructured":"W.E. Wood, Role of TSH measurements in predicting the outcome of treatment for Graves\u2019 disease following drug therapy. Postgrad. Med. J. 71, 222\u2013223 (1995)","journal-title":"Postgrad. Med. J."},{"key":"9895_CR35","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/BF03350008","volume":"12","author":"JN Talbot","year":"1989","unstructured":"J.N. Talbot, F. Duron, R. F\u00e9ron, P. Aubert, G. Milhaud, Thyroglobulin, thyrotropin and thyrotropin binding inhibiting immunoglobulins assayed at the withdrawal of antithyroid drug therapy as predictors of relapse of Graves\u2019 disease within one year. J. Endocrinol. Invest. 12, 589\u2013595 (1989)","journal-title":"J. Endocrinol. Invest."},{"key":"9895_CR36","first-page":"690","volume":"19","author":"O Ishtiaq","year":"2009","unstructured":"O. Ishtiaq, S. Waseem, M.N. Haque, N. Islam, A. Jabbar, Remission of Grave\u2019s disease after oral anti-thyroid drug treatment. J. Coll. Physicians Surg. Pak. 19, 690\u2013693 (2009)","journal-title":"J. Coll. Physicians Surg. Pak."}],"container-title":"Endocrine","original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-013-9895-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-013-9895-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-013-9895-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T14:52:37Z","timestamp":1562683957000},"score":1.0,"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,11]]},"references-count":36,"journal-issue":{"published-print":{"date-parts":[[2013,10]]},"issue":"2"},"alternative-id":["9895"],"URL":"http:\/\/dx.doi.org\/10.1007\/s12020-013-9895-0","relation":{"cites":[]},"ISSN":["1355-008X","1559-0100"],"container-title-short":"Endocrine"}